BR112022020716A2 - Anticorpos anti-tumor associados ao antígeno e usos dos mesmos - Google Patents
Anticorpos anti-tumor associados ao antígeno e usos dos mesmosInfo
- Publication number
- BR112022020716A2 BR112022020716A2 BR112022020716A BR112022020716A BR112022020716A2 BR 112022020716 A2 BR112022020716 A2 BR 112022020716A2 BR 112022020716 A BR112022020716 A BR 112022020716A BR 112022020716 A BR112022020716 A BR 112022020716A BR 112022020716 A2 BR112022020716 A2 BR 112022020716A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- antigen
- tumor antibodies
- antibodies associated
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021215P | 2020-05-07 | 2020-05-07 | |
| US202062706131P | 2020-08-03 | 2020-08-03 | |
| US202063198420P | 2020-10-16 | 2020-10-16 | |
| US202063131394P | 2020-12-29 | 2020-12-29 | |
| PCT/US2021/031055 WO2021226321A2 (en) | 2020-05-07 | 2021-05-06 | Anti-tumor associated antigen antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020716A2 true BR112022020716A2 (pt) | 2022-11-29 |
Family
ID=78468388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020716A BR112022020716A2 (pt) | 2020-05-07 | 2021-05-06 | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220107A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146702A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7821121B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230007452A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021267893A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020716A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173176A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297955A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013920A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021226321A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| EP4605425A1 (en) * | 2022-10-18 | 2025-08-27 | Zymeworks BC Inc. | Antibody-drug conjugates targeting glypican-3 and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| US9206257B2 (en) * | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗glypican-3抗體及其用於診斷及治療癌症之用途 |
| EP3431102A4 (en) * | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| CN109153719B (zh) * | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| EP3551220B1 (en) * | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3615574B1 (en) * | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| JP7382922B2 (ja) * | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CN111040036B (zh) * | 2018-10-12 | 2023-10-20 | 上海卡智生物技术有限公司 | 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用 |
-
2021
- 2021-05-06 MX MX2022013920A patent/MX2022013920A/es unknown
- 2021-05-06 CN CN202180032994.3A patent/CN115515981A/zh active Pending
- 2021-05-06 IL IL297955A patent/IL297955A/en unknown
- 2021-05-06 CA CA3173176A patent/CA3173176A1/en active Pending
- 2021-05-06 JP JP2022567223A patent/JP7821121B2/ja active Active
- 2021-05-06 AU AU2021267893A patent/AU2021267893A1/en active Pending
- 2021-05-06 EP EP21800926.4A patent/EP4146702A4/en active Pending
- 2021-05-06 WO PCT/US2021/031055 patent/WO2021226321A2/en not_active Ceased
- 2021-05-06 US US17/997,755 patent/US20230220107A1/en active Pending
- 2021-05-06 KR KR1020227041924A patent/KR20230007452A/ko active Pending
- 2021-05-06 BR BR112022020716A patent/BR112022020716A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL297955A (en) | 2023-01-01 |
| AU2021267893A1 (en) | 2022-11-03 |
| JP2023525991A (ja) | 2023-06-20 |
| EP4146702A4 (en) | 2024-07-10 |
| CN115515981A (zh) | 2022-12-23 |
| JP7821121B2 (ja) | 2026-02-26 |
| EP4146702A2 (en) | 2023-03-15 |
| CA3173176A1 (en) | 2021-11-11 |
| KR20230007452A (ko) | 2023-01-12 |
| WO2021226321A3 (en) | 2021-12-16 |
| MX2022013920A (es) | 2022-11-30 |
| WO2021226321A2 (en) | 2021-11-11 |
| US20230220107A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39416A (es) | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas | |
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
| BR112023002301A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| UY38520A (es) | Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos | |
| BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
| AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| BR112023020303A2 (pt) | Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos | |
| EA202192008A1 (ru) | Lilrb3-связывающие молекулы и варианты их применения | |
| BR112022026341A2 (pt) | Anticorpos e métodos para o tratamento de doenças associadas à claudina | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения |